Rallybio Reported Earnings

Rallybio (RLYB) reported a loss of $0.48 per share on revenue of $0.00 million for the . . Revenue fell 100.00% compared to the same quarter a year ago.

Rallybio is a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases.